News

rivaroxaban, Xarelto, safety performance, Janssen, NVAF

A new post-marketing study evaluating the safety of once-daily rivaroxaban (Xarelto) shows, in patients with non-valvular atrial fibrillation (NVAF), rates and patterns of major...

More than 10 percent of patients treated with aspirin therapy for primary cardiovascular disease prevention were likely inappropriately prescribed medication, according to a new study in the...

Savaysa, Daiichi Sankyo, edoxaban, FDA, approval, NVAF, thromboembolism

Daiichi Sankyo Co. Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Savaysa (edoxaban) tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of...

Discussions regarding late-breaking cardiovascular clinical trials among leading medical scientists are placing considerable emphasis on individualized patient care, particularly in the area of...

Wearable technologies, possible changes to stenting practices, state legislation on energy drinks, expanded use of minimally invasive heart repair procedures, and the development of a new class of...

The most accessed research studies in the Journal of the American College of Cardiology (JACC) in 2014 spanned many topics, including a blood test to rule out heart attack, an advisory...

Alere, INRatio, INRatio2, PT/INR Monitor system, correction

Alere Inc. has initiated a voluntary correction to inform United States users of the Alere INRatio and INRatio 2 PT/INR Monitor system of certain medical conditions that should not be tested with...

AHA, warfarin, antiplatelet therapy, atrial fibrillation, anti-clotting, EP lab

Long-term overtreatment with the anti-clotting drug warfarin combined with antiplatelet therapy to prevent stroke may raise the risk of dementia in people with atrial fibrillation.

DAPT study

Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop blood clots within their stents or to...

The actions — or inaction — of patients should be considered in programs designed to improve care and patient outcomes, according to a report released by the American College of Cardiology,...

New analyses and extended follow-up from the BRIGHT study demonstrated that bivalirudin remained superior to both heparin monotherapy and heparin plus tirofiban for patients with acute myocardial...

According to a new study, patients receiving six months of dual antiplatelet therapy (DAPT) after receiving a second-generation drug-eluting stent (DES) appeared to have similar outcomes to...

Study Blood Thinner Heart Attack Patients

The largest prospective longitudinal study of acute myocardial infarction (MI) patients offers unique insight into the use, safety and effectiveness of blood thinners prasugrel and clopidogrel in...

September 19, 2014 — A new study investigating different durations of triple therapy for anticoagulation after drug-eluting stent (DES) implantation demonstrated that six weeks of drug therapy was...

Professors Updated Information Aspirin Heart Attack Prevention

The first researcher in the world to discover that aspirin prevents a first attack, Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the...

U.S. Department of Justice Close Investigation PLATO Clinical Trial Ticagrelor

AstraZeneca announced it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial that tested the safety and...

July 30, 2014 — Regado Biosciences announced earlier this month it has voluntarily paused enrollment in its REGULATE-PCI trial, which was testing the safety and effectiveness of its Revolixys...

Less aggressive anticoagulation therapy, combined with low-dose aspirin, can be used safely in conjunction with a newer generation mechanical heart valve. These findings from the first phase of a...

June 3, 2014 — The U.S. Food and Drug Administration (FDA) announced it approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death and need for...